Skip to main navigation

DEFLATEHAE.COM
Investors & News
Careers
Contact

Disease Focus
Community Commitment
Scientific Approach
- Our Science
- Pipeline
Scientific Publications
About Pharvaris

Disease Focus
Community Commitment
Scientific Approach
- Our Science
- Pipeline
Scientific Publications
About Pharvaris

DEFLATEHAE.COM
Investors & News
Careers
Contact

Events

Investor Menu

IR Nav

Overview
News & Events
News Releases Events Publications
Financials
SEC Filings Quarterly Results
Stock
Stock Performance Analyst Coverage
Corporate Governance
Governance Documents Leadership Board of Directors Committee Composition
Resources
Investor FAQs Contact Us Email Alerts

Past Events

Jun 26, 2026 10:00 AM EDT

2026 Annual General Meeting of Shareholders

Supporting Materials

Annual Report 2025 4 MB

Convening Notice and Agenda 259.8 KB

Voting Proxy 198.5 KB

Executed Minutes 779.7 KB

Jun 12 - Jun 15, 2026

European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026

Supporting Materials

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial 1.2 MB

Clinical Cardiovascular Safety Assessment of Oral Deucrictibant 712.7 KB

A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema 394.9 KB

Evaluations of Safety Margins and Response to Deucrictibant Extended-Release (XR) Tablet in Combination with Deucrictibant Immediate-Release (IR) Capsule 174.5 KB

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial 262.8 KB

RAPIDe-3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks 254.2 KB

Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema 202.8 KB

CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema 200.7 KB

Jun 9, 2026

World Orphan Drug Congress (WODC) USA 2026

Supporting Materials

From Symptoms to Decisions: How Patient-Reported Outcomes Shape Trustworthy Clinical Evidence 13.9 MB

May 28 - May 31, 2026

2026 Eastern Allergy Conference (EAC)

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results Of The CHAPTER-1 Open-Label Extension Study 424.9 KB

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Phase 3 RAPIDe-3 Trial Results 267.1 KB

May 20, 2026 11:00 AM EDT

2026 RBC Capital Markets Global Healthcare Conference

Click for Webcast

May 17 - May 20, 2026

Supporting Materials

Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema: Final Results of the CHAPTER-1 Open-Label Extension Study 238.4 KB

May 13, 2026 11:40 AM EDT

BofA Securities Health Care Conference 2026

Click for Webcast

May 7 - May 9, 2026

2026 EAACI Beijing Allergy School & PUMCH Allergy Symposium

Supporting Materials

Efficacy and Safety of On-Demand Treatment of Hereditary Angioedema Attacks With Oral Deucrictibant Immediate-Release Capsule: Phase 3 RAPIDe-3 Trial Results 490.1 KB

Apr 17 - Apr 19, 2026

CIIC Spring 2026 Conference

Supporting Materials

Evaluating Safety Margins of the Use of Deucrictibant Extended-Release Tablet in Combination with Deucrictibant Immediate-Release Capsule 279.7 KB

On-Demand Treatment of Hereditary Angioedema Attacks With Oral Deucrictibant Immediate-Release Capsule: Efficacy and Safety Results of the Phase 3 RAPIDe-3 Trial 364.7 KB

Mar 27 - Mar 28, 2026

2026 Global Angioedema Leadership Conference

Supporting Materials

Results of the Phase 3 RAPIDe-3 Study of Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks 283.7 KB

End of Progression of Hereditary Angioedema Attacks with Oral Deucrictibant Immediate-Release Capsule: RAPIDe-3 Phase 3 Trial 270.9 KB

CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema 223.9 KB

Lived Patient Experiences of Hereditary Angioedema Based on Attacks and Associated Symptoms: An Innovative Conceptual Model 375.8 KB

Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema 233.3 KB

Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema (presentation) 560 KB

Pagination

Current page 1
Page 2
Page 3
…
Next page
Last page

©2026 Pharvaris N.V. © All Rights Reserved

Menu

Privacy Policy
Clinical Trial Privacy Notice
Global Privacy Laws
Terms of Use

FOLLOW US